Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) )
ClinicalTrials.gov Identifier:
NCT00344331
First received: June 23, 2006
Last updated: November 11, 2014
Last verified: September 2014

June 23, 2006
November 11, 2014
June 2006
Not Provided
Plasma Oxysterols [ Time Frame: Annual ] [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00344331 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C
Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C

This study will evaluate clinical and laboratory tests that might be useful in determining if an investigational drug can slow the progression of Niemann-Pick Disease, Type C (NPC), a genetic disorder that results in progressive loss of nervous system function. The study will: 1) look for a clinical or biochemical marker that can be used as a measure of response to treatment, and 2) define the rate of progression of biochemical marker abnormalities in a group of NPC patients who will later be invited to enroll in a treatment trial.

Patients of any age with NPC may be eligible for this study. Participants undergo the following procedures every 6 months during 4- to 5-day admissions at the NIH Clinical Center.

  • Medical evaluation, including medical history, physical exam, neurological exam, neuropsychometric evaluation, and blood and urine tests.
  • Lumbar puncture (spinal tap): A sample of cerebrospinal fluid (CSF), the fluid that bathes the brain and spinal cord, is obtained for study. After administration of a local anesthetic, a small needle is inserted in the space between the bones in the lower back where the CSF circulates below the spinal cord. A small amount of fluid is collected through the needle.
  • Eye exam and eye movement study: The pupils of the eye are dilated to examine the structures of the eyes. For the eye movement study a special contact lens is placed on the eye and the patient looks at a series of target light spots moving on a screen.
  • Hearing tests.
  • Electroretinography (in patients who can cooperate with the test) to measure the function of the retina. Before the test, the patient's pupils are dilated and an electrode (small silver disk) is taped to the forehead. The patient sits in a dark room for 30 minutes and then a special contact lens is placed on one eye after it has been numbed with drops. The contact lens senses small electrical signals generated by the retina when lights flash. During the ERG recording, the eye is stimulated with flashes of light projected inside a hollow sphere. After the test, a full eye exam is done and photographs of the retina are taken.
  • Magnetic resonance imaging (MRI): This test uses a magnetic field and radio waves to produce images of the brain and obtain information about brain chemicals. The patient lies on a table that can slide in and out of the scanner (a narrow cylinder), wearing earplugs to muffle loud knocking and thumping sounds that occur during the scanning process. Patients who cannot remain still in the scanner may be sedated for the test.
  • Psychometric testing: Patients complete questionnaires.
  • Photographs of the patient may be taken for use in teaching sessions or scientific presentations or publications, with the patient's consent. Patients may be recognizable, but are not identified by name.
  • Pregnancy test in all female patients over 10 years of age at the beginning of each admission to the Clinical Center.

Niemann-Pick type C disease (NPC) is an autosomal recessive, lysosomal storage disorder characterized by accumulation of cholesterol and gangliosides. NPC is a rare (estimated prevalence of 1:120,000-150,000) neurodegenerative disorder with a wide clinical spectrum and a variable age of onset. Classically, children with NPC demonstrate neurological dysfunction with cerebellar ataxia, dysarthria, seizures, vertical gaze palsy, motor impairment, dysphagia, psychotic episodes, and progressive dementia. In general, adolescent and adult onset forms have a more insidious onset and slower progression.

There is no effective treatment for NPC and it is a lethal disorder. A major impediment to the testing of therapeutic interventions is the lack of well-defined outcome measures. The purpose of this protocol is to obtain both baseline and rate of progression data on clinical and biochemical markers that may later be used as an outcome measure in a clinical trial.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Neimann-Pick Disease, Type C
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
300
Not Provided
Not Provided
  • INCLUSION CRITERIA:

All patients with an established diagnosis of NPC (biochemical or molecular) will be considered for this study.

Both NPC1 and NPC2 patients are eligible.

Patients of any age, sex, or ethnic background will be eligible for this study.

EXCLUSION CRITERIA:

Patients will be excluded if they cannot travel to the NIH because of their medical condition or are too ill to be cared for at home.

We will exclude NPC patients with rapidly progressive neonatal cholestasis.

Patients will be excluded if they are pregnant (a negative urine pregnancy test will be required for any menstruating female before participation in this study and at each NIH Clinical Center admission).

Patients will be excluded from the MRI section of the study if they have:

  1. Implanted cardiac pacemaker or autodefibrillators
  2. Implanted neural pacemakers
  3. Cochlear implants
  4. Metallic foreign bodies in the eye or CNS (such as a CNS aneurysmal clip)
  5. Any form of implanted wire or metal device that may concentrate radio frequency fields
  6. Pregnancy (A negative urine pregnancy test will be required for any menstruating female before participation in this study)
  7. History of an adverse reaction to sedation or anesthesia (if sedation is necessary).
  8. They do not meet the safety criteria established by the NIH Clinical Center radiology department for MRI scanning.

Although priority will be given to patients not on Zavesca, because of the potential limited number of patients, it will not be an exclusion criterion. Patients on Zavesca may be excluded from a future therapeutic trial.

Both
Not Provided
No
Contact: Nicole M Farhat, C.R.N.P. (301) 594-1765 nicole.farhat@nih.gov
Contact: Forbes D Porter, M.D. (301) 435-4432 fdporter@mail.nih.gov
United States
 
NCT00344331
060186, 06-CH-0186
Not Provided
National Institutes of Health Clinical Center (CC) ( Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) )
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not Provided
Principal Investigator: Forbes D Porter, M.D. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institutes of Health Clinical Center (CC)
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP